Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Exudative Age-Related Macular Degeneration

Interventions

DRUG

AL-78898A

Investigational treatment

DRUG

Ranibizumab

Anti-vascular endothelial growth factor (VEGF) treatment

Trial Locations (1)

Contact Alcon Call Center for Trial Locations, Fort Worth